Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medifast (MED) Amortization of Deferred Charges (2016 - 2022)

Historic Amortization of Deferred Charges for Medifast (MED) over the last 5 years, with Q2 2022 value amounting to $3000.0.

  • Medifast's Amortization of Deferred Charges changed N/A to $3000.0 in Q2 2022 from the same period last year, while for Mar 2023 it was $3000.0, marking a year-over-year decrease of 9927.36%. This contributed to the annual value of $14000.0 for FY2022, which is 8426.97% down from last year.
  • According to the latest figures from Q2 2022, Medifast's Amortization of Deferred Charges is $3000.0.
  • Medifast's Amortization of Deferred Charges' 5-year high stood at $153000.0 during Q1 2018, with a 5-year trough of $3000.0 in Q2 2022.
  • For the 3-year period, Medifast's Amortization of Deferred Charges averaged around $102000.0, with its median value being $136000.0 (2018).
  • The largest annual percentage gain for Medifast's Amortization of Deferred Charges in the last 5 years was 1217.95% (2018), contrasted with its biggest fall of 2138.73% (2018).
  • Over the past 3 years, Medifast's Amortization of Deferred Charges (Quarter) stood at $137000.0 in 2018, then fell by 5.84% to $129000.0 in 2019, then tumbled by 97.67% to $3000.0 in 2022.
  • Its Amortization of Deferred Charges stands at $3000.0 for Q2 2022, versus $11000.0 for Q1 2022 and $129000.0 for Q1 2019.